Voyager Therapeutics

101 articles with Voyager Therapeutics

• Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer

  9/14/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief Human Resources Officer.

• Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease

  9/11/2020

  NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater "On" Time without Troublesome Dyskinesia and Reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Scores, and Reduction in the Amount of Medications Up to Three Years in Patients with Parkinson's Disease

• Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020

  9/3/2020

  New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease Voyager to Participate in Upcoming September Investor Conferences CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentation

• 

  A London AI Hub, a Facility Bigger than the Louvre, Are Among the Newest Footprint Expansions in ...

  9/3/2020

  GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.

• Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

  8/10/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its second quarter 2020 financial results, program progress and corporate updates.

• Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences

  8/3/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporate updates on Monday, August 10, 2020, before the open of the U.S. financial markets.

• Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations

  8/3/2020

  Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie.

• Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  6/16/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant of a non-qualified stock option and of restricted stock units as inducements material to her entering into employment with Voyager.

• Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

  5/6/2020

  Announced 14 presentations at upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting highlighting Huntington’s disease, ALS SOD1, vectorized antibodies, novel capsids, and manufacturing

• Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting

  4/29/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 23 rd Annual Meeting taking place virtually on May 12-15, 2020. The ASGCT abstracts are now available at https://www.asgct.org/ . Details for the oral presentations are as fol

• Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial

  4/3/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today provided an update on the RESTORE-1 clinical trial of VY-AADC (NBIb-1817) for Parkinson’s disease.

• Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference

  3/9/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR) announced today the cancellation of the Company’s presentation and webcast at the Barclays Global Healthcare Conference, previously scheduled to take place on March 10, 2020 at 4:20 p.m. ET.

• Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

  3/3/2020

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its fourth quarter and full year 2019 financial results, program progress and corporate updates.

• Voyager Therapeutics to Participate in Upcoming Investor Conferences - Feb. 26, 2020

  2/26/2020

  Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will webcast management presentations as follows

• Voyager Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 3, 2020

  2/25/2020

  Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2019 financial results after market close on Tuesday, March 3, 2020.

• Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights

  11/6/2019

  Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, reported its third quarter 2019 financial results, program progress and corporate updates.

• Voyager Therapeutics to Present at the Credit Suisse Healthcare Conference

  10/31/2019

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a management presentation at the following upcoming investor conference in November:

• Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call

  10/30/2019

  Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced that it will report its third quarter 2019 financial results and corporate highlights on Wednesday, November 6, 2019 before the open of the U.S. financial markets.

• 

  Voyager Revises Sanofi Deal, Shifts Some Assets

  6/17/2019

  “Our alliance with Sanofi Genzyme has been foundational for Voyager as we optimized the development of capsids, transgenes and gene therapy delivery,” stated Andre Turenne, president and chief executive officer of Voyager. “We look forward to this new stage of the relationship and to advancing ou...

• Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting

  5/5/2019

  Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease